These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35288376)

  • 1. Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases.
    Arumahandi de Silva AN; Frommert LM; Albach FN; Klotsche J; Scholz V; Jeworowski LM; Schwarz T; Ten Hagen A; Zernicke J; Corman VM; Drosten C; Burmester GR; Biesen R
    Ann Rheum Dis; 2022 Jun; 81(6):881-888. PubMed ID: 35288376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease.
    Frommert LM; Arumahandi de Silva AN; Zernicke J; Scholz V; Braun T; Jeworowski LM; Schwarz T; Tober-Lau P; Ten Hagen A; Habermann E; Kurth F; Sander LE; Corman VM; Burmester GR; Biesen R; Albach FN; Klotsche J
    RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination.
    Habermann E; Gieselmann L; Tober-Lau P; Klotsche J; Albach FN; Ten Hagen A; Zernicke J; Ahmadov E; Arumahandi de Silva AN; Frommert LM; Kurth F; Sander LE; Burmester GR; Klein F; Biesen R
    RMD Open; 2022 Oct; 8(2):. PubMed ID: 36216410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases.
    Tzioufas AG; Bakasis AD; Goules AV; Bitzogli K; Cinoku II; Chatzis LG; Argyropoulou OD; Venetsanopoulou AI; Mavrommati M; Stergiou IE; Pezoulas V; Voulgari PV; Katsimpari C; Katechis S; Gazi S; Katsifis G; Sfontouris CI; Georgountzos AI; Liossis SN; Papagoras C; Fotiadis DI; Skopouli FN; Vlachoyiannopoulos PG; Moutsopoulos HM
    J Autoimmun; 2021 Dec; 125():102743. PubMed ID: 34757289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients.
    Kashiwado Y; Kimoto Y; Ohshima S; Sawabe T; Irino K; Nakano S; Hiura J; Yonekawa A; Wang Q; Doi G; Ayano M; Mitoma H; Ono N; Arinobu Y; Niiro H; Hotta T; Kang D; Shimono N; Akashi K; Takeuchi T; Horiuchi T
    Rheumatology (Oxford); 2024 Mar; 63(3):725-733. PubMed ID: 37289506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate significantly reduces the humoral vaccination response against SARS-CoV-2 in older but not younger patients with rheumatoid arthritis.
    Feuchtenberger M; Kovacs MS; Eder A; Nigg A; Schäfer A
    Rheumatol Int; 2022 Jun; 42(6):959-966. PubMed ID: 35429290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases.
    Aikawa NE; Kupa LVK; Medeiros-Ribeiro AC; Saad CGS; Yuki EFN; Pasoto SG; Rojo PT; Pereira RMR; Shinjo SK; Sampaio-Barros PD; Andrade DCO; Halpern ASR; Fuller R; Souza FHC; Guedes LKN; Assad APL; Moraes JCB; Lopes MRU; Martins VAO; Betancourt L; Ribeiro CT; Sales LP; Bertoglio IM; Bonoldi VLN; Mello RLP; Balbi GGM; Sartori AMC; Antonangelo L; Silva CA; Bonfa E
    Ann Rheum Dis; 2022 Jul; 81(7):1036-1043. PubMed ID: 35277389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
    Furer V; Eviatar T; Zisman D; Peleg H; Paran D; Levartovsky D; Zisapel M; Elalouf O; Kaufman I; Meidan R; Broyde A; Polachek A; Wollman J; Litinsky I; Meridor K; Nochomovitz H; Silberman A; Rosenberg D; Feld J; Haddad A; Gazzit T; Elias M; Higazi N; Kharouf F; Shefer G; Sharon O; Pel S; Nevo S; Elkayam O
    Ann Rheum Dis; 2021 Oct; 80(10):1330-1338. PubMed ID: 34127481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination.
    Andreica I; Blazquez-Navarro A; Sokolar J; Anft M; Kiltz U; Pfaender S; Vidal Blanco E; Westhoff T; Babel N; Stervbo U; Baraliakos X
    RMD Open; 2022 Sep; 8(2):. PubMed ID: 36104115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial.
    Araujo CSR; Medeiros-Ribeiro AC; Saad CGS; Bonfiglioli KR; Domiciano DS; Shimabuco AY; Silva MSR; Yuki EFN; Pasoto SG; Pedrosa T; Kupa LVK; Zou G; Pereira RMR; Silva CA; Aikawa NE; Bonfa E
    Ann Rheum Dis; 2022 Jun; 81(6):889-897. PubMed ID: 35193873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunogenicity of seasonal and pandemic influenza vaccination in autoimmune inflammatory rheumatic patients-a 6-month follow-up prospective study.
    Lakota K; Perdan-Pirkmajer K; Sodin-Šemrl S; Čučnik S; Šubelj V; Prosenc K; Mrak Poljšak K; Tomšič M; Ambrožič A; Praprotnik S
    Clin Rheumatol; 2019 May; 38(5):1277-1292. PubMed ID: 30761436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Robust neutralizing antibody response to SARS-CoV-2 mRNA vaccination in adolescents and young adults with childhood-onset rheumatic diseases.
    Yeo JG; Chia WN; Teh KL; Book YX; Hoh SF; Gao X; Das L; Zhang J; Sutamam N; Lim AJM; Poh SL; Tay SH; Nay Yaung K; Ong XM; Hazirah SN; Chua CJH; Leong JY; Wang LF; Albani S; Arkachaisri T
    Rheumatology (Oxford); 2022 Nov; 61(11):4472-4481. PubMed ID: 35199166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis.
    Stahl D; Tho Pesch C; Brück C; Esser RL; Thiele J; Di Cristanziano V; Kofler DM
    RMD Open; 2022 Oct; 8(2):. PubMed ID: 36216409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy.
    Sugihara K; Wakiya R; Shimada H; Kameda T; Nakashima S; Kato M; Miyagi T; Mizusaki M; Mino R; Nomura Y; Inoo M; Kadowaki N; Dobashi H
    Intern Med; 2022 Jul; 61(13):1953-1958. PubMed ID: 35466168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of methotrexate on the immune responses to the COVID-19 vaccines in the patients with immune-mediated inflammatory disease: A systematic review of clinical evidence.
    Al-Haideri MT; Mannani R; Kaboli R; Gharebakhshi F; Darvishzadehdeldari S; Tahmasebi S; Faramarzi F; Cotrina-Aliaga JC; Khorasani S; Alimohammadi M; Darvishi M; Akhavan-Sigari R
    Transpl Immunol; 2023 Aug; 79():101858. PubMed ID: 37236514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: A cohort study and a meta-analysis.
    Auroux M; Laurent B; Coste B; Massy E; Mercier A; Durieu I; Confavreux CB; Lega JC; Mainbourg S; Coury F
    Joint Bone Spine; 2022 Oct; 89(5):105380. PubMed ID: 35490940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of humoral immunity by repeated dose-intensified COVID-19 vaccinations in primary non- to low-responders and B cell deficient rheumatic disease patients.
    Ten Hagen A; Hermann S; Habermann E; Frommert LM; Arumahandi de Silva AN; Scholz V; Ghannam K; Klotsche J; Zernicke J; Alexander T; Burmester GR; Albach FN; Biesen R
    J Autoimmun; 2023 Feb; 135():102996. PubMed ID: 36642057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases.
    Zheng YQ; Li HJ; Chen L; Lin SP
    Sci Rep; 2022 Oct; 12(1):17955. PubMed ID: 36289319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study.
    Zeng H; Liu H; Liu Z; Zhou X; Lu X; Yan Z; Zhou Y; Dai L; Chen Y; Yang T; Yin Z; Ye Z
    Hum Vaccin Immunother; 2022 Nov; 18(5):2090176. PubMed ID: 35878733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.